United Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

United Therapeutics (Silver Spring, MD): 4 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $1.23B 2024 CMS Part D & Medicaid spend, and 34 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSilver Spring, MD
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$1.23B
2024 Medicare Part D Spend$972.7M
2024 Medicaid Spend$259.8M
California HCAI SB 17 Filings34 WAC filings (max 19.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.